253 related articles for article (PubMed ID: 33040078)
1. Splicing factor SF3B1 promotes endometrial cancer progression via regulating KSR2 RNA maturation.
Popli P; Richters MM; Chadchan SB; Kim TH; Tycksen E; Griffith O; Thaker PH; Griffith M; Kommagani R
Cell Death Dis; 2020 Oct; 11(10):842. PubMed ID: 33040078
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Splicing Factor 3b Subunit 1 (SF3B1) Reduced Cell Proliferation, Induced Apoptosis and Resulted in Cell Cycle Arrest by Regulating Homeobox A10 (HOXA10) Splicing in AGS and MKN28 Human Gastric Cancer Cells.
Zhang Y; Yuan Z; Jiang Y; Shen R; Gu M; Xu W; Gu X
Med Sci Monit; 2020 Jan; 26():e919460. PubMed ID: 31927557
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of SF3B1 inhibits cell proliferation, invasion and migration triggering apoptosis in breast cancer via aberrant splicing.
Zhang L; Zhang X; Zhang H; Liu F; Bi Y; Zhang Y; Cheng C; Liu J
Breast Cancer; 2020 May; 27(3):464-476. PubMed ID: 31919642
[TBL] [Abstract][Full Text] [Related]
4. U2AF65-Dependent SF3B1 Function in SMN Alternative Splicing.
Choi N; Liu Y; Oh J; Ha J; Zheng X; Shen H
Cells; 2020 Dec; 9(12):. PubMed ID: 33317029
[TBL] [Abstract][Full Text] [Related]
5. Splicing factor SF3B1 is overexpressed and implicated in the aggressiveness and survival of hepatocellular carcinoma.
López-Cánovas JL; Del Rio-Moreno M; García-Fernandez H; Jiménez-Vacas JM; Moreno-Montilla MT; Sánchez-Frias ME; Amado V; L-López F; Fondevila MF; Ciria R; Gómez-Luque I; Briceño J; Nogueiras R; de la Mata M; Castaño JP; Rodriguez-Perálvarez M; Luque RM; Gahete MD
Cancer Lett; 2021 Jan; 496():72-83. PubMed ID: 33038489
[TBL] [Abstract][Full Text] [Related]
6. Spliceosome component SF3B1 as novel prognostic biomarker and therapeutic target for prostate cancer.
Jiménez-Vacas JM; Herrero-Aguayo V; Gómez-Gómez E; León-González AJ; Sáez-Martínez P; Alors-Pérez E; Fuentes-Fayos AC; Martínez-López A; Sánchez-Sánchez R; González-Serrano T; López-Ruiz DJ; Requena-Tapia MJ; Castaño JP; Gahete MD; Luque RM
Transl Res; 2019 Oct; 212():89-103. PubMed ID: 31344348
[TBL] [Abstract][Full Text] [Related]
7. Dysregulated splicing factor SF3B1 unveils a dual therapeutic vulnerability to target pancreatic cancer cells and cancer stem cells with an anti-splicing drug.
Alors-Perez E; Blázquez-Encinas R; Alcalá S; Viyuela-García C; Pedraza-Arevalo S; Herrero-Aguayo V; Jiménez-Vacas JM; Mafficini A; Sánchez-Frías ME; Cano MT; Abollo-Jiménez F; Marín-Sanz JA; Cabezas-Sainz P; Lawlor RT; Luchini C; Sánchez L; Sánchez-Hidalgo JM; Ventura S; Martin-Hijano L; Gahete MD; Scarpa A; Arjona-Sánchez Á; Ibáñez-Costa A; Sainz B; Luque RM; Castaño JP
J Exp Clin Cancer Res; 2021 Dec; 40(1):382. PubMed ID: 34857016
[TBL] [Abstract][Full Text] [Related]
8. SF3B1 mutations constitute a novel therapeutic target in breast cancer.
Maguire SL; Leonidou A; Wai P; Marchiò C; Ng CK; Sapino A; Salomon AV; Reis-Filho JS; Weigelt B; Natrajan RC
J Pathol; 2015 Mar; 235(4):571-80. PubMed ID: 25424858
[TBL] [Abstract][Full Text] [Related]
9. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
Chang AY; Zhou YJ; Iyengar S; Pobiarzyn PW; Tishchenko P; Shah KM; Wheeler H; Wang YM; Loria PM; Loganzo F; Woo SR
J Biol Chem; 2021 Nov; 297(5):101277. PubMed ID: 34619148
[TBL] [Abstract][Full Text] [Related]
10. Splicing modulation as novel therapeutic strategy against diffuse malignant peritoneal mesothelioma.
Sciarrillo R; Wojtuszkiewicz A; El Hassouni B; Funel N; Gandellini P; Lagerweij T; Buonamici S; Blijlevens M; Zeeuw van der Laan EA; Zaffaroni N; Deraco M; Kusamura S; Würdinger T; Peters GJ; Molthoff CFM; Jansen G; Kaspers GJL; Cloos J; Giovannetti E
EBioMedicine; 2019 Jan; 39():215-225. PubMed ID: 30581150
[TBL] [Abstract][Full Text] [Related]
11. SF3B1 inhibition disrupts malignancy and prolongs survival in glioblastoma patients through BCL2L1 splicing and mTOR/ß-catenin pathways imbalances.
Fuentes-Fayos AC; Pérez-Gómez JM; G-García ME; Jiménez-Vacas JM; Blanco-Acevedo C; Sánchez-Sánchez R; Solivera J; Breunig JJ; Gahete MD; Castaño JP; Luque RM
J Exp Clin Cancer Res; 2022 Jan; 41(1):39. PubMed ID: 35086552
[TBL] [Abstract][Full Text] [Related]
12. Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia.
Wang L; Brooks AN; Fan J; Wan Y; Gambe R; Li S; Hergert S; Yin S; Freeman SS; Levin JZ; Fan L; Seiler M; Buonamici S; Smith PG; Chau KF; Cibulskis CL; Zhang W; Rassenti LZ; Ghia EM; Kipps TJ; Fernandes S; Bloch DB; Kotliar D; Landau DA; Shukla SA; Aster JC; Reed R; DeLuca DS; Brown JR; Neuberg D; Getz G; Livak KJ; Meyerson MM; Kharchenko PV; Wu CJ
Cancer Cell; 2016 Nov; 30(5):750-763. PubMed ID: 27818134
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the aberrant splicing of MAP3K7 induced by cancer-associated SF3B1 mutation.
Li Z; Zhao B; Shi Y; Liang Y; Qian R; Wan Y
J Biochem; 2021 Sep; 170(1):69-77. PubMed ID: 33751071
[TBL] [Abstract][Full Text] [Related]
14. Titration of SF3B1 Activity Reveals Distinct Effects on the Transcriptome and Cell Physiology.
Kim Guisbert KS; Mossiah I; Guisbert E
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348896
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of SF3b1 by pladienolide B evokes cycle arrest, apoptosis induction and p73 splicing in human cervical carcinoma cells.
Zhang Q; Di C; Yan J; Wang F; Qu T; Wang Y; Chen Y; Zhang X; Liu Y; Yang H; Zhang H
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):1273-1280. PubMed ID: 30963795
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the RNA Splicing Factor SF3B1 Promote Tumorigenesis through MYC Stabilization.
Liu Z; Yoshimi A; Wang J; Cho H; Chun-Wei Lee S; Ki M; Bitner L; Chu T; Shah H; Liu B; Mato AR; Ruvolo P; Fabbri G; Pasqualucci L; Abdel-Wahab O; Rabadan R
Cancer Discov; 2020 Jun; 10(6):806-821. PubMed ID: 32188705
[TBL] [Abstract][Full Text] [Related]
17. Cancer-associated SF3B1 mutations affect alternative splicing by promoting alternative branchpoint usage.
Alsafadi S; Houy A; Battistella A; Popova T; Wassef M; Henry E; Tirode F; Constantinou A; Piperno-Neumann S; Roman-Roman S; Dutertre M; Stern MH
Nat Commun; 2016 Feb; 7():10615. PubMed ID: 26842708
[TBL] [Abstract][Full Text] [Related]
18. Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.
Kyei GB; Meng S; Ramani R; Niu A; Lagisetti C; Webb TR; Ratner L
mBio; 2018 Nov; 9(6):. PubMed ID: 30401776
[TBL] [Abstract][Full Text] [Related]
19. The pre-mRNA splicing and transcription factor Tat-SF1 is a functional partner of the spliceosome SF3b1 subunit via a U2AF homology motif interface.
Loerch S; Leach JR; Horner SW; Maji D; Jenkins JL; Pulvino MJ; Kielkopf CL
J Biol Chem; 2019 Feb; 294(8):2892-2902. PubMed ID: 30567737
[TBL] [Abstract][Full Text] [Related]
20. Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer.
Chen K; Xiao H; Zeng J; Yu G; Zhou H; Huang C; Yao W; Xiao W; Hu J; Guan W; Wu L; Huang J; Huang Q; Xu H; Ye Z
Clin Cancer Res; 2017 Jul; 23(13):3428-3441. PubMed ID: 27879367
[No Abstract] [Full Text] [Related]
[Next] [New Search]
